SanBio Co (4592.T) Stock Price

SanBio Co Price

JPX·CLOSED
921.00JPY+1.00 (+0.11 %)
Market closed

Revenue has compounded at 13.9% per year over the past 6 years to 447.23 M JPY. SanBio Co's net margin stands at -1,153.3%, down from -84.1% several years earlier. Analysts set a median price target of 2,040.00 JPY, implying 121.5% above the current price. Of 11 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 2% above its 52-week low.

SanBio Co stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of SanBio Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how SanBio Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing SanBio Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

SanBio Co Stock Price History
DateSanBio Co Price
8/3/2026921.00 JPY
7/31/2026920.00 JPY
7/30/2026904.00 JPY
7/29/2026902.00 JPY
7/28/2026926.00 JPY
7/27/2026969.00 JPY
7/24/2026957.00 JPY
7/23/20261,001.00 JPY
7/22/20261,005.00 JPY
7/21/20261,067.00 JPY
7/17/20261,035.00 JPY
7/16/20261,073.00 JPY
7/15/20261,043.00 JPY
7/14/2026995.00 JPY
7/13/20261,006.00 JPY
7/10/2026993.00 JPY
7/9/2026999.00 JPY
7/8/2026952.00 JPY
7/7/20261,023.00 JPY
7/6/20261,055.00 JPY
7/3/20261,056.00 JPY
7/2/20261,022.00 JPY
7/1/20261,000.00 JPY
6/30/2026993.00 JPY
6/29/20261,027.00 JPY
6/26/2026935.00 JPY
6/25/2026981.00 JPY
6/24/2026959.00 JPY
6/23/2026974.00 JPY
6/22/2026981.00 JPY
6/19/20261,039.00 JPY
6/18/20261,064.00 JPY
6/17/20261,184.00 JPY
6/16/20261,235.00 JPY
6/15/20261,198.00 JPY
6/12/20261,211.00 JPY
6/11/20261,174.00 JPY
6/10/20261,218.00 JPY
6/9/20261,245.00 JPY
6/8/20261,237.00 JPY
6/5/20261,279.00 JPY
6/4/20261,261.00 JPY
6/3/20261,260.00 JPY
6/2/20261,272.00 JPY
6/1/20261,281.00 JPY
5/29/20261,459.00 JPY
5/28/20261,441.00 JPY
5/27/20261,488.00 JPY
5/26/20261,413.00 JPY
5/25/20261,438.00 JPY
5/22/20261,538.00 JPY
5/21/20261,523.00 JPY
5/20/20261,415.00 JPY
5/19/20261,581.00 JPY
5/18/20261,692.00 JPY
5/15/20261,876.00 JPY
5/14/20261,916.00 JPY
5/13/20262,026.00 JPY
5/12/20262,237.00 JPY
5/11/20262,255.00 JPY
5/8/20262,258.00 JPY
5/7/20262,100.00 JPY
5/1/20261,970.00 JPY
4/30/20261,875.00 JPY
4/28/20261,977.00 JPY
4/27/20262,002.00 JPY
4/24/20262,048.00 JPY
4/23/20262,123.00 JPY
4/22/20262,209.00 JPY
4/21/20262,180.00 JPY
4/20/20262,182.00 JPY
4/17/20262,091.00 JPY
4/16/20262,019.00 JPY
4/15/20262,019.00 JPY
4/14/20261,953.00 JPY
4/13/20261,932.00 JPY
4/10/20261,985.00 JPY
4/9/20262,038.00 JPY
4/8/20262,110.00 JPY
4/7/20261,956.00 JPY
4/6/20261,921.00 JPY
4/3/20261,845.00 JPY
4/2/20261,825.00 JPY
4/1/20261,937.00 JPY
3/31/20261,781.00 JPY
3/30/20261,827.00 JPY
3/27/20261,880.00 JPY
3/26/20261,836.00 JPY
3/25/20261,927.00 JPY
3/24/20261,846.00 JPY
3/23/20261,772.00 JPY
3/19/20261,919.00 JPY
3/18/20262,048.00 JPY
3/17/20261,985.00 JPY
3/16/20262,020.00 JPY
3/13/20261,995.00 JPY
3/12/20262,020.00 JPY
3/11/20262,124.00 JPY
3/10/20262,195.00 JPY
3/9/20262,098.00 JPY
3/6/20262,166.00 JPY
3/5/20262,075.00 JPY
3/4/20261,951.00 JPY
3/3/20262,067.00 JPY
3/2/20262,209.00 JPY
2/27/20262,258.00 JPY
2/26/20262,154.00 JPY
2/25/20262,126.00 JPY
2/24/20262,170.00 JPY
2/20/20262,258.00 JPY
2/19/20262,390.00 JPY
2/18/20262,332.00 JPY
2/17/20262,161.00 JPY
2/16/20262,256.00 JPY
2/13/20262,044.00 JPY
2/12/20262,142.00 JPY
2/10/20261,970.00 JPY
2/9/20261,877.00 JPY
2/6/20261,854.00 JPY
2/5/20261,921.00 JPY
2/4/20261,903.00 JPY
2/3/20261,865.00 JPY
2/2/20261,849.00 JPY
1/30/20261,849.00 JPY
1/29/20261,832.00 JPY
1/28/20261,840.00 JPY
1/27/20261,898.00 JPY
1/26/20261,933.00 JPY
1/23/20261,984.00 JPY
1/22/20261,890.00 JPY
1/21/20261,899.00 JPY
1/20/20261,916.00 JPY
1/19/20262,021.00 JPY
1/16/20261,949.00 JPY
1/15/20261,935.00 JPY
1/14/20261,741.00 JPY
1/13/20261,682.00 JPY
1/9/20261,697.00 JPY
1/8/20261,755.00 JPY
1/7/20261,702.00 JPY
1/6/20261,750.00 JPY
1/5/20261,637.00 JPY
12/30/20251,690.00 JPY
12/29/20251,718.00 JPY
12/26/20251,614.00 JPY
12/25/20251,632.00 JPY
12/24/20251,597.00 JPY
12/23/20251,619.00 JPY
12/22/20251,539.00 JPY
12/19/20251,562.00 JPY
12/18/20251,525.00 JPY
12/17/20251,612.00 JPY
12/16/20251,639.00 JPY
12/15/20251,665.00 JPY
12/12/20251,647.00 JPY
12/11/20251,702.00 JPY
12/10/20251,955.00 JPY
12/9/20251,733.00 JPY
12/8/20251,725.00 JPY
12/5/20251,745.00 JPY
12/4/20251,643.00 JPY
12/3/20251,562.00 JPY
12/2/20251,756.00 JPY
12/1/20252,027.00 JPY
11/28/20252,205.00 JPY
11/27/20252,267.00 JPY
11/26/20252,209.00 JPY
11/25/20252,191.00 JPY
11/21/20252,230.00 JPY
11/20/20252,341.00 JPY
11/19/20252,338.00 JPY
11/18/20252,390.00 JPY
11/17/20252,444.00 JPY
11/14/20252,554.00 JPY
11/13/20252,628.00 JPY
11/12/20252,613.00 JPY
11/11/20252,520.00 JPY
11/10/20252,540.00 JPY
11/7/20252,473.00 JPY
11/6/20252,734.00 JPY
11/5/20252,819.00 JPY
11/4/20252,845.00 JPY
10/31/20252,830.00 JPY
10/30/20252,794.00 JPY
10/29/20252,720.00 JPY
10/28/20252,821.00 JPY
10/27/20252,798.00 JPY
10/24/20252,678.00 JPY
10/23/20252,756.00 JPY
10/22/20252,918.00 JPY
10/21/20252,809.00 JPY
10/20/20252,711.00 JPY
10/17/20252,690.00 JPY
10/16/20253,000.00 JPY
10/15/20253,695.00 JPY
10/14/20253,635.00 JPY
10/10/20253,850.00 JPY
10/9/20253,850.00 JPY
10/8/20253,540.00 JPY
10/7/20253,450.00 JPY
10/6/20253,395.00 JPY
10/3/20253,335.00 JPY
10/2/20252,931.00 JPY
10/1/20252,431.00 JPY
9/30/20252,496.00 JPY
9/29/20252,557.00 JPY
9/26/20252,485.00 JPY
9/25/20252,541.00 JPY
9/24/20252,772.00 JPY
9/22/20252,876.00 JPY
9/19/20252,680.00 JPY
9/18/20252,342.00 JPY
9/17/20252,413.00 JPY
9/16/20252,324.00 JPY
9/12/20252,393.00 JPY
9/11/20252,361.00 JPY
9/10/20252,442.00 JPY
9/9/20252,461.00 JPY
9/8/20252,483.00 JPY
9/5/20252,485.00 JPY
9/4/20252,440.00 JPY
9/3/20252,402.00 JPY
9/2/20252,500.00 JPY
9/1/20252,405.00 JPY
8/29/20252,317.00 JPY
8/28/20252,323.00 JPY
8/27/20252,322.00 JPY
8/26/20252,396.00 JPY
8/25/20252,396.00 JPY
8/22/20252,530.00 JPY
8/21/20252,506.00 JPY
8/20/20252,575.00 JPY
8/19/20252,606.00 JPY
8/18/20252,660.00 JPY
8/15/20252,695.00 JPY
8/14/20252,721.00 JPY
8/13/20252,755.00 JPY
8/12/20252,647.00 JPY
8/8/20252,727.00 JPY
8/7/20252,651.00 JPY
8/6/20252,445.00 JPY
Access this data via the Eulerpool API
Get Free API Key

SanBio Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
0.00 JPY
-5.80 B JPY
-3.39 B JPY
Jan 1, 2022
0.00 JPY
-6.62 B JPY
-4.68 B JPY
Jan 1, 2023
0.00 JPY
-7.90 B JPY
-5.56 B JPY
Jan 1, 2024
0.00 JPY
-4.54 B JPY
-2.64 B JPY
Jan 1, 2025
0.00 JPY
-3.52 B JPY
-2.88 B JPY
Jan 1, 2026 (e)
94.94 M JPY
0.00 JPY
-3.78 B JPY
Jan 1, 2027 (e)
3.45 B JPY
0.00 JPY
-1.53 B JPY
Jan 1, 2028 (e)
8.58 B JPY
0.00 JPY
-2.44 B JPY

SanBio Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 1:08 PM
 
REVENUEB JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
EBITB JPY
EBIT MARGIN%
NET INCOMEB JPY
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e
0.203.231.170.950.490.740.45–––––0.093.458.58
–1,482.84-63.64-19.17-48.3751.22-39.68––––––3,572.34148.58
456.8628.8679.3998.21190.20125.78208.50–––––98.2198.2198.21
0.930.930.930.930.930.930.930.930.930.930.930.930.093.398.43
-0.582.25-1.13-1.93-4.38-3.73-5.49-5.80-6.62-7.90-4.54-3.52–––
-286.2769.65-95.83-203.58-893.47-503.78-1,227.29––––––––
-0.591.74-0.99-1.84-3.94-2.92-5.16-3.39-4.68-5.56-2.64-2.88-3.78-1.53-2.44
–-394.74-156.9185.73114.71-25.8976.61-34.3638.1718.86-52.449.0031.02-59.5659.86
38.2039.1843.6044.8945.3748.5451.1151.7951.7957.9265.3268.8768.8768.8768.87
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales SanBio Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue SanBio Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare SanBio Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares SanBio Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against SanBio Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

SanBio Co stock margins

The SanBio Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SanBio Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SanBio Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
98.19 %
- %
- %
Jan 1, 2022
98.19 %
- %
- %
Jan 1, 2023
98.19 %
- %
- %
Jan 1, 2024
98.19 %
- %
- %
Jan 1, 2025
98.19 %
- %
- %
Jan 1, 2026 (e)
98.19 %
0.00 %
-3,977.34 %
Jan 1, 2027 (e)
98.19 %
0.00 %
-44.24 %
Jan 1, 2028 (e)
98.19 %
0.00 %
-28.45 %

SanBio Co Stock Revenue, EBIT, Earnings per Share

The SanBio Co earnings per share therefore indicates how much revenue SanBio Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 JPY
-112.03 JPY
-65.38 JPY
Jan 1, 2022
0.00 JPY
-127.84 JPY
-90.33 JPY
Jan 1, 2023
0.00 JPY
-136.39 JPY
-95.99 JPY
Jan 1, 2024
0.00 JPY
-69.50 JPY
-40.48 JPY
Jan 1, 2025
0.00 JPY
-51.06 JPY
-41.86 JPY
Jan 1, 2026 (e)
1.38 JPY
0.00 JPY
-54.83 JPY
Jan 1, 2027 (e)
50.13 JPY
0.00 JPY
-22.17 JPY
Jan 1, 2028 (e)
124.60 JPY
0.00 JPY
-35.45 JPY

SanBio Co business model & stock analysis

SanBio Co Ltd is a leading bio-pharmaceutical company focused on the development of products for the treatment of serious neurological diseases. The company was founded in Japan in 2000 and has since become a multinational company with offices in the USA and Europe. Answer: SanBio Co Ltd is a bio-pharmaceutical company that specializes in developing products for the treatment of serious neurological diseases. It was founded in Japan in 2000 and has expanded to become a multinational company with offices in the USA and Europe.

SanBio Co SWOT Analysis

Strengths

  • Strong research and development capabilities in regenerative medicine.
  • Established partnerships with leading academic institutions and biotech companies.
  • Diverse and innovative product pipeline, addressing critical unmet medical needs.
  • Solid financial position, with sufficient resources for expansion and growth.

Weaknesses

  • Limited market presence and brand recognition compared to larger competitors.
  • Dependence on a few key research programs and products.
  • Vulnerability to regulatory and legal challenges in the healthcare industry.
  • Relatively small workforce, which may limit capacity for simultaneous projects.

Opportunities

  • Growing demand for regenerative medicine solutions as the global population ages.
  • Increasing collaboration opportunities with pharmaceutical companies for product development.
  • Expansion into new geographical markets with high unmet medical needs.
  • Potential to leverage advancements in technology for more efficient and cost-effective therapies.

Threats

  • Intense competition from established pharmaceutical and biotech companies.
  • Stringent regulatory requirements and long approval processes for new therapies.
  • Economic downturns and healthcare system reforms impacting funding and reimbursement.
  • Potential ethical and public perception challenges associated with stem cell therapies.

SanBio Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

SanBio Co historical P/E ratio, EBIT multiple, and P/S ratio

SanBio Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

SanBio Co shares outstanding

The number of shares of SanBio Co was 68.87 M in 2025. This indicates how many shares SanBio Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
51.79 M Stocks
Jan 1, 2022
51.79 M Stocks
Jan 1, 2023
57.92 M Stocks
Jan 1, 2024
65.32 M Stocks
Jan 1, 2025
68.87 M Stocks
Jan 1, 2026 (e)
68.87 M Stocks
Jan 1, 2027 (e)
68.87 M Stocks
Jan 1, 2028 (e)
68.87 M Stocks

Current SanBio Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
54.55 % (6)
Sell
45.45 % (5)
12M Price Target
2,040.00
Last Price
921.00
Currency
JPY
12M Return Potential
121.50 %
LTM Return
0 %

SanBio Co Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/16/2020-JPY-26.39 MJPY-2020 Q4
12/14/2018-16.26JPY-203.00 MJPY-2019 Q3
9/13/2018-JPY-144.13 MJPY-2019 Q2
3/17/2017-JPY-194.88 MJPY-2017 Q4
3/16/2016-JPY-711.51 MJPY-2016 Q4

SanBio Co shareholder structure

% Name
17.74622%
Kawanishi (Toru)
Kawanishi (Toru)
8.70858%
Mori (Keita)
Mori (Keita)
4.16023%
Nomura Securities Co., Ltd.
Nomura Securities Co., Ltd.
1.02358%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.33020%
State Street Investment Management (US)
State Street Investment Management (US)
0.28214%
Simplex Asset Management Co., Ltd.
Simplex Asset Management Co., Ltd.

SanBio Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.8%
Float Shares
-
Shares Outstanding
-

SanBio Co Executives and Management Board

8 members · avg. age 60 · 13 % women

Management

TK

Mr. Toru Kawanishi (55)

Chairman of the Board, Executive Officer, Representative Director · since 2013

–
KM

Mr. Keita Mori (57)

President, Chief Executive Officer, Executive Officer, CEO of Subsidiary, Representative Director · since 2013

–
NT

Mr. Naoki Tsukahara

Managing Executive Officer

–
YS

Mr. Yoshihiro Sumiya

Executive Officer, Director of Business Administration

–
SH

Mr. Shinya Hirata

Executive Officer, Chief Director of Research and Development

–
KN

Mr. Keizo Nakata

Executive Officer, Chief Director of Production

–

Board of Directors

NK

Mr. Noboru Kotani (68)

Independent Director

–

Frequently asked questions about SanBio Co

The business model of SanBio Co Ltd focuses on developing and commercializing regenerative medicine products. SanBio Co Ltd specializes in the research and development of innovative cell therapies to treat neurological disorders. With a strong emphasis on stem cell-based therapies, the company aims to provide effective and safe treatments for conditions such as traumatic brain injury, stroke, and chronic motor deficits. Through its extensive research, partnership collaborations, and dedication to clinical trials, SanBio Co Ltd aims to revolutionize the field of regenerative medicine and improve the quality of life for patients worldwide.

SanBio Co Ltd is primarily active in the biotechnology and pharmaceutical industries.

SanBio Co Ltd faces competition from pharmaceutical companies that operate in the regenerative medicine field. Some of the main competitors include Mesoblast Limited, Athersys Inc., and Healios K.K. These companies are also focused on developing innovative therapies for treating neurological disorders and injuries, similar to SanBio. However, SanBio has established its unique position in the market with its proprietary regenerative cell therapy products.

SanBio Co Ltd is a pioneering regenerative medicine company based in Japan. Founded in 2005, SanBio focuses on developing and commercializing groundbreaking cell-based therapies for neurological disorders. With a strong commitment to advancing scientific research, SanBio has made significant strides in neurorehabilitation and regenerative medicine. The company has successfully conducted clinical trials and received approvals from regulatory authorities, demonstrating the effectiveness and safety of its innovative therapies. SanBio's dedication to improving patients' lives through cutting-edge treatments has earned it a prominent position in the field of regenerative medicine.

Some significant milestones achieved by SanBio Co Ltd include the successful completion of Phase II clinical trials for their investigational therapeutic product SB623, which showed promising results in treating motor deficits caused by stroke. Additionally, SanBio Co Ltd received Fast Track designation from the U.S. FDA for SB623, recognizing its potential to address unmet medical needs. The company also expanded its product pipeline and entered into collaborations with global pharmaceutical companies to further advance their regenerative medicine technologies. SanBio Co Ltd continues to strive towards making notable advancements in the field of regenerative medicine and improving patient outcomes.

SanBio Co Ltd is primarily present in Japan.

SanBio Co Ltd represents the values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on advancing regenerative medicine, SanBio is committed to developing novel therapies that address unmet medical needs. By leveraging their proprietary technology, SB623, SanBio aims to restore function and improve the quality of life for patients suffering from neurological disorders. Their dedication to scientific excellence, ethical conduct, and transparency fosters trust among stakeholders. Through their pioneering research and development efforts, SanBio Co Ltd is contributing to advancements in the field of regenerative medicine, bringing hope to patients worldwide.

Analysts currently set an average price target of 2,091.00 JPY for the SanBio Co stock (median: 2,040.00 JPY), implying +127.0 % versus the latest price. The consensus is based on 11 analyst ratings.

SanBio Co Analyst Price Targets 2026

11 analysts currently rate the SanBio Co stock: 0 recommend buying, 6 holding and 5 selling. For 2026, analysts expect SanBio Co to generate revenue of 94.94 M JPY and earnings per share of -54.83 JPY.

SanBio Co Analyst Price Targets 2026

Converted at the current exchange rate, the SanBio Co share trades at 5.07 EUR (921.00 JPY).

SanBio Co Ltd is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological diseases. It was originally founded in Japan and its business model includes research and development, clinical trials, partnerships, and distribution. The research and development team at SanBio focuses on developing novel drugs and therapies based on stem cell and genomic research. They utilize state-of-the-art technologies to identify and optimize novel drug candidates to enable successful treatment of neurological diseases. SanBio is committed to conducting clinical trials by partnering with renowned medical centers and research institutions in Japan, the US, and Europe. This collaboration aims to confirm the effectiveness and safety of clinical candidates for broad use in healthcare. SanBio has also formed partnerships with other companies worldwide for the marketing and distribution of its products. These partnerships aim to make SanBio's products and therapies accessible globally. SanBio offers various therapy products for neurological diseases, including "SB623" for traumatic brain injury and "SB509" for Amyotrophic Lateral Sclerosis (ALS). SB623 is being developed to treat patients with skull-brain injuries. It is a cell therapy derived from reprogrammed human neural stem cells from a donor's bone marrow. SB509 is being developed for the treatment of ALS and is a gene therapy that produces neurotrophic factors to promote the survival of motor neurons. Both products have the potential to meet the need for effective therapies for neurological diseases. In summary, SanBio Co Ltd offers innovative therapeutics for the treatment of neurological diseases. The company's business model includes research and development of novel therapies, conducting clinical trials, partnerships, and product distribution. SanBio has the commitment and resources to meet the demand for effective therapeutics for treating neurological diseases.

The expected revenue of SanBio Co is 94.94 M JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of SanBio Co is -3.78 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of SanBio Co is currently -16.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SanBio Co stock.

The price-to-sales ratio (P/S) of SanBio Co is currently 668.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SanBio Co stock.

The Eulerpool Quality Score for SanBio Co is 2/10.

The ISIN of SanBio Co is JP3336750009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of SanBio Co is A14SRH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of SanBio Co is 4592.T. The ticker symbol is used to trade SanBio Co shares on the stock exchange.

SanBio Co paid dividends every year for the past 0 years.

SanBio Co is assigned to the 'Health' sector.

The dividends of SanBio Co are distributed in JPY.

All fundamentals and in-depth analysis of SanBio Co

Our stock analysis for SanBio Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SanBio Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

SanBio Co Stock
SanBio Co Revenue→
SanBio Co Stock
SanBio Co Net Income→
SanBio Co Stock
SanBio Co P/E→
SanBio Co Stock
SanBio Co P/S→
SanBio Co Stock
SanBio Co EBIT→
SanBio Co Stock
SanBio Co Dividend→
SanBio Co Stock
SanBio Co Directors Dealings→
SanBio Co Stock
SanBio Co Stocks→
SanBio Co Stock
SanBio Co Market capitalization→
SanBio Co Stock
SanBio Co Debt→
SanBio Co Stock
SanBio Co Liabilities→
SanBio Co Stock
SanBio Co Equity→
SanBio Co Stock
SanBio Co AAQS→
SanBio Co Stock
SanBio Co Employees→
SanBio Co Stock
SanBio Co ROE→
SanBio Co Stock
SanBio Co ROA→
SanBio Co Stock
SanBio Co ROCE→
SanBio Co Stock
SanBio Co News→
SanBio Co Stock
SanBio Co Analyst Price Targets→

Health Stocks

Sanbo Hospital Management GroupSanara MedtechSangamo TherapeuticsSanai Health Industry Group CoSangani HospitalsSana BiotechnologySanigen CoSamsung Pharm CoSanionaSamsung Biologics CoSanjivani ParanteralSamsrita LabsAll Stocks A–Z →